Polypeptides

US5766883A · kind A · utility

Assignee

• Delta Biotechnology Limited · GB

Inventors

• David J. Ballance · Berwyn, US
• Andrew R. Goodey · Nottingham, GB

Key dates

• Filing date: Nov 17, 1993
• Grant date: Jun 16, 1998
• Expiry date: Nov 17, 2013

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/50
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

A fusion polypeptide comprising, as at least part of the N-terminal portion thereof, an N-terminal portion of HSA or a variant thereof and, as at least part of the C-terminal portion thereof, another polypeptide except that, when the said N-terminal portion of HSA is the 1-n portion where n is 369 to 419 or a variant thereof then the said polypeptide is one of various specified entities. The HSA-like portion may have additional N-terminal residues, such as secretion leader sequences (signal sequences). The C-terminal portion is preferably the amino terminal fragment of human urokinase-type plasminogen activator. The N-terminal and C-terminal portions may be cleavable to yield the isolated C-terminal portion, with the N-terminal portion having served to facilitate secretion from the host. Such cleavage can be achieved in yeast using a sequence cleavable by the KEX2 protease of S. cerevisiae.